Gilead Sciences (GILD) Payables (2009 - 2026)

Gilead Sciences has reported Payables for 18 years, with the latest figure at $645.0 million in Q1 2026.

• For the quarter ending Q1 2026, Payables fell 12.48% year-over-year to $645.0 million; the trailing twelve-month figure through Mar 2026 stood at $645.0 million (down 12.48% YoY), and the FY2025 full-year result was $715.0 million, down 14.17% from the prior year.
• Payables for Q1 2026 stood at $645.0 million, down from $715.0 million in the prior quarter.
• The five-year high for Payables was $905.0 million in Q4 2022, with the low at $537.0 million in Q2 2024.
• Historically, Payables has averaged $672.6 million across 5 years, with a median of $622.0 million in 2023.
• Annual changes were most pronounced in 2023 — Payables tumbled 39.23% — and 2024, when it jumped 54.1%.
• Gilead Sciences' Payables stood at $905.0 million in 2022, then plunged by 39.23% to $550.0 million in 2023, then surged by 51.45% to $833.0 million in 2024, then decreased by 14.17% to $715.0 million in 2025, then fell by 9.79% to $645.0 million in 2026.
• The last three Payables figures came in at $645.0 million (Q1 2026), $715.0 million (Q4 2025), and $808.0 million (Q3 2025), per Business Quant data.